Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A. Sperone P, et al. Among authors: berruti a. Endocr Relat Cancer. 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. Print 2010 Jun. Endocr Relat Cancer. 2010. PMID: 20410174 Clinical Trial.
Intermittent everolimus administration for malignant insulinoma.
Baratelli C, Brizzi MP, Tampellini M, Scagliotti GV, Priola A, Terzolo M, Pia A, Berruti A. Baratelli C, et al. Among authors: berruti a. Endocrinol Diabetes Metab Case Rep. 2014;2014:140047. doi: 10.1530/EDM-14-0047. Epub 2014 Sep 1. Endocrinol Diabetes Metab Case Rep. 2014. PMID: 25298880 Free PMC article.
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators. Imbimbo M, et al. Cancer Treat Rev. 2018 Dec;71:76-87. doi: 10.1016/j.ctrv.2018.10.001. Epub 2018 Oct 5. Cancer Treat Rev. 2018. PMID: 30366202
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Berruti A, et al. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184. BMC Cancer. 2014. PMID: 24628963 Free PMC article. Clinical Trial.
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi MP, Sculli CM, Berruti A, Gorzegno G, Magnino A, Sperti E, Miraglia S, Forti L, Alabiso O, Aglietta M, Harris A, Dogliotti L. Tampellini M, et al. Among authors: berruti a. Br J Cancer. 2006 Jul 3;95(1):13-20. doi: 10.1038/sj.bjc.6603204. Epub 2006 Jun 13. Br J Cancer. 2006. PMID: 16773070 Free PMC article. Clinical Trial.
522 results